View source for Genetex

{{Multiple issues|
{{notability|Companies|date=May 2018}}
{{primary sources|date=May 2018}}
}}
'''GeneTex''' is a life science, biotechnology company that develops, licenses, and sells a product catalog of research reagents related to the study of the biomedical sciences. The company provides [[antibodies]] and [[protein]]s for use by academic and industry investigators involved in basic and translational research in biology and medicine.<ref>{{Cite web|title=About Us {{!}} GeneTex|url=https://www.genetex.com/Company/About_US|access-date=2019-07-18|website=www.genetex.com}}</ref>{{Infobox company
| name = GeneTex, Inc
| logo =
| logo_size =
| founders = [[Joel B. Baseman]], [[Eva Y.-H. P. Lee]], [[Wen-Hwa Lee]], [[C. Kent Osborne]]
| type = Private
| industry = [[Biotechnology]], [[List of life sciences|Life Sciences]]
| founded = 1997
| areas_served = International
| hq_location_city = [[Irvine, CA]]
| hq_location_country =
| products = [[Antibody#Research applications|Research Antibodies]], kits and assays for biological research
| num_employees = 50-200
| website = {{URL|www.genetex.com}}
}}
In 2016, GeneTex together with antibody research companies Novus Biologicals, R&D Systems, and Atlas Antibodies joined the International Working Group on Antibody Validation (IWGAV) with the intention to help standardize [[best practice]]s in antibody validation.<ref>{{Cite web|url=https://www.genetex.com/MarketingMaterial/Index/five_pillars|title=GeneTex Five Pillars of Antibody Validation}}</ref><ref>{{cite journal |last1=Uhlen |first1=Mathias |last2=Bandrowski |first2=Anita |last3=Carr |first3=Steven |last4=Edwards |first4=Aled |last5=Ellenberg |first5=Jan |last6=Lundberg |first6=Emma |last7=Rimm |first7=David L. |last8=Rodriguez |first8=Henry |last9=Hiltke |first9=Tara |last10=Snyder |first10=Michael |last11=Yamamoto |first11=Tadashi |title=A proposal for validation of antibodies |journal=Nature Methods |date=October 2016 |volume=13 |issue=10 |pages=823–827 |doi=10.1038/nmeth.3995 |pmid=27595404 |s2cid=34259132 |pmc=10335836 }}</ref>
== Recombinant monoclonal antibody technology ==
GeneTex has incorporated [[recombinant antibodies|recombinant]] [[monoclonal antibody]] technology into its product development platform. This technology has numerous well-documented advantages, with consistency of performance being of paramount significance. The protocol employed is a multi-parameter approach based on [[fluorescence-activated cell sorting]] (FACS) to isolate antigen-specific [[memory B cell]]s from an immunized animal, with subsequent cloning of the antibody variable-region [[gene]]s into an [[Immunoglobulin G]] (IgG) backbone and expression in mammalian cells. The entire development procedure can be completed in weeks.<ref>{{Cite web|title=Recombinant Antibodies {{!}} GeneTex|url=https://www.genetex.com/Product/Overview/primary_antibodies/Recombinant-Antibodies|access-date=2020-10-30|website=www.genetex.com}}</ref>
==References==
{{Reflist}}
[[Category:Biotechnology companies of the United States]]
[[Category:American companies established in 1997]]
[[Category:1997 establishments in California]]
[[Category:Companies based in Irvine, California]]